Literature DB >> 7977947

Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma.

D G Bostwick1, M K Dousa, B G Crawford, P C Wollan.   

Abstract

Neuroendocrine cells are thought to have a regulatory role in prostatic epithelial growth and may be prognostically useful in prostatic adenocarcinoma. To determine the extent of neuroendocrine differentiation in high-grade prostatic intraepithelial neoplasia (PIN), a putative precursor of cancer, we studied the immunohistochemical expression of 10 markers in 26 radical prostatectomy specimens with PIN and adenocarcinoma. Expression was measured as mean percent of positive cases and positive high-power (x40) fields. The highest percentage of cases showed immunoreactivity for serotonin (73%, PIN; 54%, carcinoma), neuron-specific enolase (NSE) (67%, PIN; 46%, carcinoma), chromogranin (62%, PIN; 65%, carcinoma), and human chorionic gonadotropin (hCG) (30%, PIN; 22%, carcinoma); the remaining markers showed immunoreactivity in fewer than 5% of cases (somatostatin, calcitonin, corticotropin) or in no cases (thyrotropin, prolactin, and glucagon). At least one of the markers was present in 88% of cases of PIN and 92% of carcinoma. Non-neoplastic epithelial cells expressed serotonin, NSE, chromogranin, and hCG in every case, and the expression was significantly greater than in PIN and cancer. Stepwise regression analysis revealed the following positive correlations: chromogranin expression in PIN and patient age, NSE expression in cancer and number of lymph node metastases, and hCG expression in cancer and percentage of Gleason pattern 5; serotonin expression in PIN and cancer did not correlate with any of the clinical and pathologic factors. Neuroendocrine differentiation is downregulated in prostatic carcinogenesis, with intermediate levels of expression in PIN compared with normal cells and carcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977947     DOI: 10.1097/00000478-199412000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  11 in total

1.  beta hCG as a prognostic marker in adenocarcinoma of the prostate.

Authors:  M T Sheaff; J E Martin; D F Badenoch; S I Baithun
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

2.  TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Authors:  Z Mounir; F Lin; V G Lin; J M Korn; Y Yu; R Valdez; O H Aina; G Buchwalter; A B Jaffe; M Korpal; P Zhu; M Brown; R D Cardiff; J L Rocnik; Y Yang; R Pagliarini
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

3.  Cells in various benign and malignant conditions of the human prostate express different antigenic phenotypes.

Authors:  O I Turhan; N E Aydin; O Sariyüce; S Ozkan
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 4.  Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance.

Authors:  R Montironi; R Mazzucchelli; F Algaba; A Lopez-Beltran
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

5.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

6.  A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.

Authors:  Primo N Lara; Jeff Longmate; Christopher P Evans; David I Quinn; Przemyslaw Twardowski; Gurkamal Chatta; Edwin Posadas; Walter Stadler; David R Gandara
Journal:  Anticancer Drugs       Date:  2009-03       Impact factor: 2.248

7.  Incidence of neuroendocrine cells in the seminal vesicles and the prostate--an immunohistochemical study.

Authors:  Hans Jörg Sommerfeld; Alan Wayne Partin; Jürgen Pannek
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

8.  Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.

Authors:  M Hammad Ather; Farhat Abbas; Nuzhat Faruqui; Mohammad Israr; Shahid Pervez
Journal:  BMC Urol       Date:  2008-12-30       Impact factor: 2.264

Review 9.  Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle.

Authors:  Alfredo Berruti; Francesca Vignani; Lucianna Russo; Valentina Bertaglia; Mattia Tullio; Marcello Tucci; Massimiliano Poggio; Luigi Dogliotti
Journal:  Open Access J Urol       Date:  2010-07-23

10.  Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.

Authors:  Giorgio Mauri; Elena Jachetti; Barbara Comuzzi; Matteo Dugo; Ivano Arioli; Silvia Miotti; Sabina Sangaletti; Emma Di Carlo; Claudio Tripodo; Mario P Colombo
Journal:  Oncotarget       Date:  2016-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.